Clinical implication of endothelial dysfunction in patients with essential arterial hypertension and urate dysbolism with renal damage
- 作者: Stakhova T.Y.1, Pulin A.A.1, Severova M.M.1, Shovskaya T.N.1, Minakova E.G.1, Oleynikova E.B.1, Lebedeva M.V.1, Stakhova TY.2, Pulin AA2, Severova MM2, Shovskaya TN2, Minakova EG2, Oleinikova EB2, Lebedeva MV2
-
隶属关系:
- I.M. Sechenov First Moscow State Medical University
- 期: 卷 83, 编号 10 (2011)
- 页面: 36-40
- 栏目: Editorial
- ##submission.dateSubmitted##: 10.04.2020
- ##submission.datePublished##: 15.10.2011
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30922
- ID: 30922
如何引用文章
全文:
详细
Material and methods. A total of 50 patients with essential hypertension of degree I-II free of associated clinical conditions entered the trial. The study group consisted of 40 patients with hyperuricemia, the control group - of 10 patients with normal blood serum levels of uric acid.
Results. The study group patients versus controls had significantly higher albuminuria (93.5±1.7 and 60.7±2.2 mg/l; p < 0.001), plasmic concentration of endotheline-1 (6.8±0.3 and 4.9±0.2 pg/ml; p < 0.001)and thickness of the intima-media complex of the common carotid artery (1.36±0.02 and 1.1±0.04; p < 0.001). All the indices correlated directly and significantly.
Conclusion. Patients with arterial hypertension of the first-second degree with persistent elevated levels of uric acid in blood serum had significantly higher levels of ED markers: albuminuria, plasmic endothelin concentration. Hyperuricemia and ED in such patients lead to more active progression of atherosclerotic vascular lesion.
作者简介
Tat'yana Stakhova
Email: tstakhova@mail.ru
Andrey Pulin
Email: andreypulin@gmail.com
Mariya Severova
Email: mseverova@mail.ru
Tat'yana Shovskaya
Email: knvpb@mma.ru
Elena Minakova
Email: knvpb@mma.ru
Elena Oleynikova
Email: knvpb@mma.ru
Marina Lebedeva
Email: marinaamica@mail.ru
T Stakhova
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
A Pulin
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
M Severova
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
T Shovskaya
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
E Minakova
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
E Oleinikova
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
M Lebedeva
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
参考
- Шальнова С. А., Деев А. Д., Оганов Р. Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваск. терапия и профилактика 2005; 1: 3-8.
- Российское медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр). М.; 2008.
- ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J. Hypertens. 2007; 21: 1011-1053.
- Fang J., Alderman M. H. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA, 2000; 283: 2404-2410.
- Culleton B. F., Larson M. G., Kannel W. B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med. 1999;131:7-13.
- Baker J. F., Krishnan E., Chen L., Schumacher H. R. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am. J. Med. 2005; 118: 816-826.
- Bos M. J., Koudstaal P. J., Hofman A. et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study. Stroke 2006; 37: 1503-1507.
- Kim S. Y., Guevara J. P., Kim K. M. et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthr. and Rheum. 2009; 61: 885-892.
- Kanellis J., Kang D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 2005; 25: 39-42.
- Feig D. I., Kang D. H., Johnson R. J. Uric acid and cardiovascular risk. N. Engl. Med. 2008; 359: 1811-1821.
- Mazzali M., Kanellis J., Han L. et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal Physiol. 2002; 282: F991-F997.
- Mazzali M., Hughes J., Kim Y. G. et al. Elevated uric acid increases blood pressure in rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
- Khosla U. M., Zharikov S., Finch J. L. et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739- 1742.
- Sanchez-Lozada L. G., Tapia E., Lopez-Molina R. et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J. Physiol. Renal Physiol. 2007; 292: F1238- F1244.
- Landmesser U., Drexler H. The clinical significance of endotelial dysfunction. Curr. Opin. Cardiol. 2005; 20(6): 547-551.
- Johnson R. J., Kang D. H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
- Сагинова E. A., Фомин B. B., Моисеев С. В. и др. Поражение почек при ожирении. Тер. арх. 2007; 6: 88-94.
- Mazzone Т. Adipose tissue and the vessel wall. Curr. Drug Targets 2007; 8(11): 1190-1195.
- Балахонова T. B. Ультразвуковая диагностика атеросклероза. B кн.: Чазов Е. И. (ред.). Руководство по атеросклерозу и ишемической болезни сердца. М.: Медиа Медика; 2007.
- Ishizaka N., Ishizaka Y., Toda E. I. et al. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1038-1044.
- Ishizaka N., Ishizaka Y., Toda E. I. et al. Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis 2007; 192(1): 131-137.
- Kawamoto R., Tomita H., Oka Y., Ohtsuka N. Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intern. Med. 2006; 45: 605-614.
- Iribarren C., Folsom A. R., Eckfeldt J. H. et al. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities. Ann. Epidemiol. 1996; 6: 331-340.
- Бритов A. H. Оценка сердечно-сосудистого риска при ведении больных артериальной гипертонией. Кардиоваск. тер. и профилакт. 2003; 3: 9-17.
- Шоничев Д. А., Балкаров И. М., Лебедева М. В. и др. АГ у лиц с нарушением обмена мочевой кислоты. Тер. аpx. 1999; 6: 17-20.
- Kanellis J., Kang D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 2005; 25: 39-42.
- Мухин H. A., Моисеев B. C., Кобалава Ж. Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. арх. 2004; 6: 39-46.
- Мухин Н. А., Фомин В. В., Моисеев С. В. и др. Микроальбуминурия - интегральный маркер кардиоренальных взаимоотношений при артериальной гипертонии. Consilium Medicum 2007; 9(5): 13-18.